Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Jose Baselga" Clear advanced filters

  • Targeting the Erbb family of receptor tyrosine kinases, specifically ERBB1 (EGFR) and ERBB2, has led to successful cancer therapies. However, many patients will progress on these therapies. As we learn more about this pivotal receptor family, can we devise better methods of targeting it?

    • José Baselga
    • Sandra M. Swain
    Reviews
    Nature Reviews Cancer
    Volume: 9, P: 463-475

  • Estrogen-deprivation strategies with aromatase inhibitors are superior to tamoxifen in the adjuvant, neoadjuvant and advanced breast-cancer settings in postmenopausal patients. Short-term hormonal resistance especially in the HER2-positive patient population, however, is a significant issue with these endocrine agents. The authors discuss the progress made in our understanding of resistance to endocrine therapy, and provide insights regarding the management of patients with hormone receptor-positive/HER2-positive advanced breast cancer.

    • Aleix Prat
    • José Baselga
    Reviews
    Nature Clinical Practice Oncology
    Volume: 5, P: 531-542

  • TheTP53gene is mutated in 50% of reported cancer cases and the p53 pathway is often partially inactivated in the remaining 50%. Clinical trials assessing agents that exploit the p53 system are ongoing. This Review discusses the mechanism of action of these treatments and the future of p53-based therapy.

    • Chit Fang Cheok
    • Chandra S. Verma
    • David P. Lane
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 25-37

  • This Perspectives article describes how phase I trials assessing the efficacy of targeted therapies should examine not only safety and toxicity, but also the appropriate patient population. Based on the experience of their own academic institution, Rodón and colleagues explain how to build a pre-screening programme in early drug development.

    • Jordi Rodón
    • Cristina Saura
    • Josep Tabernero
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 9, P: 359-366

  • There have been great advances in the treatment of patients with breast cancer, with novel targeted agents having a great impact on treatment at all stages of the disease trajectory. In this Review, the treatment options for patients with metastatic disease are discussed—focussing on agents that target breast cancer cells, breast cancer stem cells and the breast microenvironment.

    • Dimitrios Zardavas
    • José Baselga
    • Martine Piccart
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 191-210

  • Agents targeting the PI3K/AKT/mTOR pathway have been shown to be safe and effective in treating a number of tumour types. This Review outlines the background to these inhibitors and discusses the second-generation inhibitors of this pathway. The authors propose that the way forward for the development of inhibitors of the PI3K/AKT/mTOR pathway might be a systems biology approach and biomarker-driven studies.

    • Jordi Rodon
    • Rodrigo Dienstmann
    • Josep Tabernero
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 143-153